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Enterovirus 71 (EV71) has emerged as a significant cause of brainstem encephalitis 
and acute flaccid paralysis in Taiwan. It may be complicated by autonomic nervous 
system dysregulation and pulmonary edema (PE). Cytokines in the central nervous 
system and systemic inflammatory responses play important roles in the pathogen-
esis of EV71-associated PE. Pathogenesis-based management with intravenous 
immunoglobulin and milrinone has been associated with reduced mortality in 
children with severe EV71 infections.
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Human enteroviruses (EVs) include the well-
recognized polioviruses, Coxsackie A and B viruses, 
ECHO viruses, and numbered EVs. As global efforts to 
eradicate poliovirus-associated poliomyelitis pro-
ceed, however, EV71 has emerged as an important 
neurological threat responsible for recent regional 
outbreaks in the West Pacific area since 1998,1 espe-
cially in Taiwan.2,3 Approximately 250 children have 
died in Taiwan as a result of EV71 infections between 
1998 and the present, according to the Centers for 
Disease Control, Taiwan.
Southern Taiwan has experienced several EV71 
epidemics: in the 1998 outbreak, 89% of patients 
were aged younger than 5 years. Hand foot and 
mouth disease occurred in 79% of the children and 
central nervous system (CNS) involvement in 35%. 
The predominant neurological presentations were 
myoclonic jerks (68%), vomiting (53%), and ataxia 
(35%).2 Of greatest concern was brainstem encepha-
litis (BE), which was the cardinal feature of EV71 CNS 
involvement. A subset of affected children devel-
oped acute flaccid paralysis.4 BE presents clinically 
with various combinations of symptoms including 
myoclonic jerks, ataxia, tremors, nystagmus, ocu-
lomotor and cranial nerve palsies, and can progress 
to seizures. Some children with BE rapidly develop 
pulmonary edema (PE) and/or hemorrhage, with 
subsequent cardiopulmonary collapse and shock. 
Based on the 1998 EV71 outbreak in Taiwan, several 
clinical stages of the disease were defined by some 
medical centers.5 We stratified EV71 BE into three 
important critical stages according to disease sever-
ity: uncomplicated BE, autonomic nervous system 
(ANS) dysregulation, and PE. We then developed 
effective ways to manage patients.
We observed that the mean cerebrospinal fluid 
(CSF) concentration of interleukin (IL)-1β in children 
with EV71-associated PE was significantly higher than 
that in children with uncomplicated BE. IL-6 and 
interferon (IFN)-γ levels were also significantly higher 
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in patients with EV71-associated PE and ANS dys-
regulation than in cases with uncomplicated BE.6 
Significant elevations of plasma IL-10, IL-13, and 
IFN-γ levels were observed in patients with PE. 
Patients with PE also had lower numbers of circulat-
ing CD4+ T-cells, CD8+ T-cells, and natural killer cells.7 
Both the CNS and systemic inflammatory responses 
to infection play important, but distinctly different, 
roles in the pathogenesis of EV71-associated PE.
The mainstay of treatment for EV71 disease is 
supportive management. We suggest that all patients 
who demonstrate the neurological symptoms and 
signs described above should be hospitalized. If the 
patient has been diagnosed with uncomplicated BE, 
close monitoring of the myoclonic jerks and vital 
signs, including body temperature, blood pressure 
(BP) and heart rate (HR), is mandatory. The target 
CNS organ in EV71 infection is the brainstem, rather 
than the cerebrum, and increased intracranial pres-
sure is therefore rarely encountered and the admin-
istration of osmotic diuretics is usually unnecessary. 
If the patient has frequent myoclonic jerks, cold 
sweating, mottled skin, and/or tachycardia (> 150/
min) and/or elevation of BP (> 2 standard devia-
tions of age-matched BP), the patient has deterio-
rated to the stage of BE with ANS dysregulation. 
All patients at this stage should receive intensive care 
and their hemodynamics should be monitored.8 On 
diagnosis of ANS dsyregulation, it is critical that in-
travenous immunoglobulin (IVIG) infusion be admin-
istered as soon as possible. Furthermore, patients 
presenting with acute flaccid paralysis combined 
with pleocytosis in the CSF should also receive IVIG 
infusion, because EV71 can be transmitted to the 
CNS through retrograde axonal pathways.9 IVIG 
1 g/kg should be initiated for the first day, and if 
ANS dsyregulation does not improve, a second dose 
should be administered the following day. IVIG treat-
ment can reduce the production of IL-6 and IL-8 
during the early phase of EV71-associated ANS dys-
regulation, and prevent further progression to PE.10 
A better survival rate might have been achieved in 
previous outbreaks by earlier therapy or larger doses 
of IVIG. If patients have a HR persistently > 180/
min, and high BP, milrinone can be administered 
simultaneously. Advanced airway management is also 
important, especially prophylactic intubation and 
adequate oxygenation; otherwise, hypoxic-ischemic 
encephalopathy can result in patients with PE, in 
addition to the direct brainstem insult caused by 
EV71.11
In patients with PE, the fatality rate has been as 
high as 90%, before the introduction of milrinone. 
All fatalities occurred within 6−12 hours after ad-
mission, if not managed promptly. Pure inotropic 
agents have been associated with poorer outcomes, 
while milrinone has both inotropic and vasodilating 
properties. It is a cyclic nucleotide phosphodieste-
rase inhibitor subtype III that increases cardiac out-
put, and reduces systemic vascular resistance and 
pulmonary capillary wedge pressure, without caus-
ing excessive increases in myocardial oxygen con-
sumption. The drug is administered intravenously at 
a dosage range of 0.35−0.55 μg/kg/minute. Therapy 
is continued for only 72 hours, as long-term use 
poses the potential risk of arrhythmia. In one study, 
the milrinone-treated group had reduced mortality 
in comparison with the non-treated group (36.4% 
vs. 92.3%),12 and sympathetic tachycardia was de-
creased. There was also a significant decrease in 
IL-13 levels in milrinone-treated patients, compared 
to controls. Milrinone therapy may provide a useful 
therapeutic approach for treating life-threatening 
EV71 infections. In order to further test the efficacy 
of milrinone, a collaborative study with the Children’s 
Hospital No.1, Ho Chi Minh City, Vietnam is under-
way and preliminary results are encouraging.
EV71 reemerged in the Taiwanese community in 
2008 with a new genotype, after 2 years’ occulta-
tion. Up to the middle of August 2008, 340 severe 
cases and 10 fatal cases have been reported in 
Taiwan. Using the pathogenesis-based management 
program described above, we have successfully 
treated more than 50 severe cases, including six 
patients whose infections were complicated by PE, 
at our institution in 2008. This noninvasive and ef-
fective program can reduce the morbidity and mor-
tality due to EV71 infection in children, while we 
await the development of a vaccine.
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